3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
9
Sarcoma
8
Breast
5
Thoracic
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Lymphoma, T-Cell, Cutaneous
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Interventions
Cyclophosphamide
886
Rituximab
864
Vincristine
382
Etoposide
381
fludarabine
342
Cytarabine
341
Doxorubicin
340
fludarabine phosphate
319
Methotrexate
310
Dexamethasone
283
Prednisone
282
Lenalidomide
245
Filgrastim
228
Melphalan
200
Peripheral Blood Stem Cell Transplantation
184
Radiotherapy
175
Whole-Body Irradiation
172
Busulfan
165
Mycophenolic Acid
161
venetoclax
158
Bendamustine Hydrochloride
158
Granulocyte Colony-Stimulating Factor
151
Tacrolimus
145
ibrutinib
144
Bortezomib
138
obinutuzumab
125
Gemcitabine
113
Cyclosporine
110
Antilymphocyte Serum
103
Carmustine
100
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
talimogene laherparepvec
×
Lymphoid
×
Clear all
NCT03458117
2022-03-18
20139157 T-VEC
University of Zurich
Phase 1
Completed
26 enrolled